ABIRA MEDICAL LABORATORIES, LLC v. HEALTHSMART BENEFIT SOLUTIONS, INC.

CourtDistrict Court, D. New Jersey
DecidedMarch 28, 2025
Docket3:23-cv-03791
StatusUnknown

This text of ABIRA MEDICAL LABORATORIES, LLC v. HEALTHSMART BENEFIT SOLUTIONS, INC. (ABIRA MEDICAL LABORATORIES, LLC v. HEALTHSMART BENEFIT SOLUTIONS, INC.) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
ABIRA MEDICAL LABORATORIES, LLC v. HEALTHSMART BENEFIT SOLUTIONS, INC., (D.N.J. 2025).

Opinion

NOT FOR PUBLICATION

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

ABIRA MEDICAL LABORATORIES, LLC d/b/a GENESIS DIAGNOSTICS, Plaintiff, Civil Action No. 23-3791 (RK) (IBD) v. OPINION HEALTHSMART BENEFIT SOLUTIONS, INC., et al., Defendants.

KIRSCH, District Judge THIS MATTER comes before the Court upon Defendants HealthSmart, HealthSmart Benefit Solutions, Inc., HealthSmart Benefits Management, LLCs, and HealthSmart Holdings I, LLC’s (together “HealthSmart’” or “Defendants”) Motion to Dismiss the Amended Complaint brought by Plaintiff Abira Medical Laboratories, LLC d/b/a Genesis Diagnostics (“Abira” or “Plaintiff’). (ECF Nos. 41; 41-2, “Def. Mot.”) Plaintiff opposed the Motion (ECF No. 42, “Pl. Opp.”’), and Defendants replied (ECF No. 43, “Pl. Rep.”). The Court has considered the parties’ submissions and resolves the matter without oral argument pursuant to Federal Rule of Civil Procedure 78 and Local Civil Rule 78.1. For the reasons set forth below, Defendants’ Motion is GRANTED. 1. BACKGROUND This case is one in a series of dozens of cases in this District brought by Plaintiff against various insurers, alleging non-payment for medical laboratory services rendered. Plaintiff claims to be a business that “performed clinical laboratory, toxicology, pharmacy, genetics, and addiction rehabilitation testing services.” (ECF No. 8, “Am. Compl.” § 31.) Plaintiff bases its claims on the

existence of “insurance contracts” between “insurance companies and the[ir] insureds/claimants” that “require the Defendants to pay for laboratory testing of the insured/claimants’ specimen.” (Id. { 37.) According to Plaintiff, the relationship between Plaintiff, the insureds, and Defendants would generally proceed as follows: first, at a doctor’s office or other local facility, the insureds would “submit[] specimen,” such as molecular swabs or blood samples, that would then be shipped to Plaintiff's laboratory. Ud. J 38(i).) Since the relevant “insurance contracts” included “Benefits clauses or provisions requiring Defendants to pay for the laboratory testing” of specimen, the insured would “provide[] their insurance information to” Plaintiff, so that Plaintiff could collect payment from Defendants. (/d. {| 38(ii).) After that, the laboratory would test the specimen, provide the results to the appropriate recipient, and submit the bill, “typically called a claim,” to Defendants for payment. (fd. J 38(iii).) Plaintiffs primary contention is that, contrary to the above process, Defendant never paid for any tests. (Jd. J 44(v).) In total, Plaintiff alleges that Defendant owes $58,774 for unpaid laboratory testing charges incurred by their insured customers. (Id. J 60.) Not only does Plaintiff allege that it was denied payment owed via contract, it alleges that Defendants induced it to continue providing testing under the false promise that the claims would not be denied and payment would be forthcoming. (See id. J 45.) In particular, in cursory fashion, the Amended Complaint recounts that “Defendants’ representatives (“Chelsea D.,’ ‘Adrn. P.’, and ‘Brady’) communicated with Abira’s representatives at the end of 2019 and in early 2020; they did not deny eligibility of the claims, thus creating the impression that payment would be forthcoming.” Ud.) According to Plaintiff, this “impression” was not accidental, as “Defendants intended to watch Abira’s claims grow, knowing that they would later refuse to pay Abira for a substantial amount of the outstanding claims.” (Ud. 9 45(ii); see also id. § 68 (Defendants

“impressed upon Abira that Defendants would pay Abira for the lab testing services to Defendants’ insureds/claimants”); {| 84 (describing “the impression that Defendants would pay Abira for performing testing services to Defendants’ insureds/claimants”).) Some key facts are absent from the operative pleading. Although the Amended Complaint alleges non-payment pursuant to a variety of “insurance contracts” and claimants, Plaintiff does not identify any of the insureds/claimants or how many are involved in this case, and does not identify, append, quote, or cite any insurance contract. Plaintiff, contradicting itself, also alleges two separate bases for privity with the (unidentified) insurance contracts: first, as an “assignee of the insurance contracts, as evidenced by [claimants] providing their insurance information to Abira,” (id. {| 39), and second, as an “authorized representative . . . pursuant to 29 C.F.R. § 2560.503-1(b)(4)” Gd. J 49(év)). Plaintiff asserts nine causes of action against Defendants and other unidentified affiliates and unnamed companies and individuals: (1) Breach of Contract; (2) Breach of Implied Covenant of Good Faith and Fair Dealing; (3) Fraudulent Misrepresentation; (4) Negligent Misrepresentation; (5) Promissory Estoppel; (6) Equitable Estoppel; (7) Quantum Meruit and Unjust Enrichment; (8) Violation of the Families First Coronavirus Response Act (“FFCRA”) and the Coronavirus Aid, Relief, Economic Security (“CARES”) Act; and (9) Violation of the New Jersey Consumer Fraud Act (“NJCFA”), N.J. Stat. Ann. § 56:8-2, under which Plaintiff seeks treble damages for a total of $176,322. (Id. J9 51-120.) On July 14, 2023, Defendants removed the case to this Court from the Superior Court of New Jersey, Mercer County, Law Division, based on diversity jurisdiction pursuant to 28 U.S.C.

§ 1332. (ECF No.1.) Plaintiff filed an Amended Complaint on August 31, 2023. (See Am. Compl.) On December 2, 2024, Defendants filed their Motion to Dismiss. (See ECF No. 41.)! In the nearly fourteen months that elapsed between Plaintiff’s filing of the Amended Complaint and Defendants’ filing of the Motion to Dismiss, the parties exchanged documents informally to try to ascertain the identities of the various insureds who allegedly received laboratory testing from Plaintiff. (See Def. Mot. at Plaintiff purportedly sent Defendants a spreadsheet that identified some information about the claims in dispute, including “the member names, dates of service, and billed amount” but was only able to provide four “claim numbers” out of 50 insureds. (/d. (citing ECF No. 41-3, “Ex. 1”).) Using the four identified claim numbers, Defendants located the corresponding insurance plan documents and appended short excerpts from three of them to their Motion. (See ECF No. 41-3.) According to Defendants, “[a] review of the plans of insurance implicated by the 4 Matched Claims reveals that 3 of the 4 involved members [] were enrollees of ERISA governed health benefits plans . . . and that 2 of the 4 plans at issue in

‘On August 15, 2024, this case was reassigned to the Undersigned. (ECF No. 30.) * Plaintiff and Defendants both attached exhibits to their briefs that are extraneous to the pleadings. (See ECF Nos. 41-3, 42-1.) Defendants attached a spreadsheet of potential claimants and three excerpts of healthcare plan documents. (ECF Nos. 41-3.) Plaintiff attached screenshots of various medical forms. (ECF No, 42-1.) “As a general matter, a district court ruling on a motion to dismiss may not consider matters extraneous to the pleadings. However, an exception to the general rule is that ‘a document integral to or explicitly relied upon in the complaint’ may be considered ‘without converting the motion [to dismiss] into one for summary judgment.’” In re Burlington Coat Factory Sec. Litig., 114 F.3d 1410, 1426 (3d Cir. 1997) (citations omitted).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Shaw v. Delta Air Lines, Inc.
463 U.S. 85 (Supreme Court, 1983)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Burtch v. Milberg Factors, Inc.
662 F.3d 212 (Third Circuit, 2011)
Skypala v. Mortgage Electronic Registration Systems, Inc.
655 F. Supp. 2d 451 (D. New Jersey, 2009)
Starkey v. Estate of Nicolaysen
796 A.2d 238 (Supreme Court of New Jersey, 2002)
Iliadis v. Wal-Mart Stores, Inc.
922 A.2d 710 (Supreme Court of New Jersey, 2007)
Video Pipeline, Inc. v. Buena Vista Home Entertainment, Inc.
210 F. Supp. 2d 552 (D. New Jersey, 2002)
Alexander Menkes v. Prudential Insurance Co of Ame
762 F.3d 285 (Third Circuit, 2014)
North Jersey Brain & Spine Center v. Aetna, Inc.
801 F.3d 369 (Third Circuit, 2015)
Michael J. Thieme v. Bernice F. Aucoin-Thieme(076683)
151 A.3d 545 (Supreme Court of New Jersey, 2016)
Kulwicki v. Dawson
969 F.2d 1454 (Third Circuit, 1992)
Rhonda Wilson v. USI Insurance Services LLC
57 F.4th 131 (Third Circuit, 2023)

Cite This Page — Counsel Stack

Bluebook (online)
ABIRA MEDICAL LABORATORIES, LLC v. HEALTHSMART BENEFIT SOLUTIONS, INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/abira-medical-laboratories-llc-v-healthsmart-benefit-solutions-inc-njd-2025.